Authors
Renata Machado Pinto, Gabriela Luz Castelo Branco de Souza, Gustavo Moraes Magalhães, Isabely Gelinski, Luiz Felipe Macedo Silva
Published in
Jornal de pediatria. Pages 101590. Jul 17, 2026. Epub Jul 17, 2026.
Abstract
To evaluate the incidence and epidemiological, clinical, and laboratory characteristics of Central Precocious Puberty (CPP) before, during, and after the COVID-19 pandemic in Goiás, Brazil.
This retrospective, longitudinal, observational study with a quantitative approach was conducted in Goiás using administrative records of high-cost medication dispensing. All patients registered in the state dispensing center who initiated treatment between 2018 and 2023 were included. Data were analyzed using the Statistical Package for Social Sciences (IBM Corporation, Armonk, USA), version 26.0. Statistical significance was set at 5% (p < 0.05).
A total of 910 CPP treatment requests were evaluated, including 153 before the pandemic, 390 during 2020-2021, and 367 during 2022-2023. This corresponded to increases of 154% and 140% during the pandemic and post-pandemic periods, respectively (p < 0.001). From 2020 onward, patients started gonadotropin-releasing hormone analog therapy at younger ages (104.84 ± 12.52 vs. 107.17 ± 13.42 months; p = 0.027), but showed more advanced pubertal development, with higher Tanner stages (B/G stage 4: 15.9% and 21.4% vs. 8.6%; p = 0.035) and higher stimulated LH levels (22.39 ± 16.81 and 24.64 ± 22.13 vs. 19.87 ± 18.08 mIU/mL; p = 0.046).
CPP incidence increased significantly in Goiás during and after the COVID-19 pandemic. Patients also presented more advanced clinical and laboratory features than those diagnosed before the pandemic.
PMID:
42468908
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0